The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.

The aims of this study were to estimate the effects of demographics, location, severity of multiple sclerosis (MS), comorbidities, plan type, coinsurance levels, and time of entry into the sample on the use of disease-modifying agents.